Tarextumab

From Wikipedia, the free encyclopedia
Jump to navigation Jump to search
Tarextumab
Monoclonal antibody
Type?
SourceHuman
TargetNotch 2, Notch 3
Clinical data
SynonymsOMP-59R5
ATC code
  • none
Legal status
Legal status
  • Investigational
Identifiers
CAS Number
ChemSpider
  • none
UNII
Chemical and physical data
FormulaC6338H9804N1700O1990S48
Molar mass143.2 kDa g·mol−1


Tarextumab (formerly OMP-59R5) is a fully human monoclonal antibody targeting the Notch 2/3 receptors. It is being tested as a possible treatment for cancer. In Jan 2015 the US FDA granted orphan drug designation to tarextumab for the treatment of pancreatic cancer and lung cancer.[1] Two early stage clinical trials have reported encouraging results.[1]

See also[edit]

References[edit]

  1. ^ a b "Tarextumab Gets FDA Orphan Drug Designation for Lung, Pancreatic Cancer". 2015.